Key Points
- Alphatec EVP David Sponsel sold 21,106 shares on Dec. 10 at an average price of $20.79 for a total of $438,793.74, leaving him with 439,767 shares (a 4.58% reduction).
- The Dec. 10 sale continues a pattern of insider selling this year — Sponsel previously sold 137,445 shares on Sept. 18 and 70,000 shares on Oct. 24, among other transactions.
- For context, Alphatec has a market cap of about $2.97 billion, recently beat quarterly estimates (EPS $0.03 vs. -$0.06) with revenue of $196.5M (+30.4% YoY), and holds a consensus analyst rating of Moderate Buy with an average target of $22.45.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 21,106 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $20.79, for a total transaction of $438,793.74. Following the completion of the transaction, the executive vice president directly owned 439,767 shares in the company, valued at approximately $9,142,755.93. This represents a 4.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
David Sponsel also recently made the following trade(s):
- On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The stock was sold at an average price of $21.45, for a total transaction of $21,192.60.
- On Friday, October 24th, David Sponsel sold 70,000 shares of Alphatec stock. The shares were sold at an average price of $16.18, for a total value of $1,132,600.00.
- On Friday, September 19th, David Sponsel sold 2,555 shares of Alphatec stock. The stock was sold at an average price of $15.34, for a total value of $39,193.70.
- On Thursday, September 18th, David Sponsel sold 137,445 shares of Alphatec stock. The stock was sold at an average price of $15.09, for a total value of $2,074,045.05.
Alphatec Price Performance
ATEC stock opened at $19.96 on Friday. The firm has a market cap of $2.97 billion, a P/E ratio of -19.19 and a beta of 1.08. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. Alphatec Holdings, Inc. has a 1 year low of $8.69 and a 1 year high of $22.66. The stock has a 50-day simple moving average of $18.42 and a 200-day simple moving average of $15.08.
Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analysts' expectations of $182.78 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm's revenue was up 30.4% compared to the same quarter last year. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Loop Capital set a $25.00 price target on shares of Alphatec in a report on Wednesday. Stifel Nicolaus began coverage on shares of Alphatec in a research report on Tuesday, October 28th. They issued a "buy" rating and a $20.00 price objective for the company. Wall Street Zen lowered Alphatec from a "buy" rating to a "hold" rating in a research report on Saturday, December 6th. Morgan Stanley set a $23.00 price target on Alphatec in a research note on Tuesday, December 2nd. Finally, Wells Fargo & Company increased their price target on Alphatec from $14.00 to $16.00 and gave the company an "overweight" rating in a report on Thursday, October 16th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.45.
View Our Latest Research Report on ATEC
Institutional Investors Weigh In On Alphatec
Institutional investors have recently modified their holdings of the stock. LPL Financial LLC lifted its position in shares of Alphatec by 1.2% during the first quarter. LPL Financial LLC now owns 418,061 shares of the medical technology company's stock worth $4,211,000 after purchasing an additional 4,826 shares during the last quarter. Vanguard Group Inc. increased its holdings in Alphatec by 0.8% in the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock valued at $60,990,000 after buying an additional 45,792 shares during the last quarter. Deutsche Bank AG raised its stake in Alphatec by 11.8% during the first quarter. Deutsche Bank AG now owns 1,185,235 shares of the medical technology company's stock valued at $12,018,000 after buying an additional 124,785 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Alphatec by 4.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company's stock worth $413,000 after buying an additional 1,792 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Alphatec during the 1st quarter worth approximately $973,000. Institutional investors and hedge funds own 66.35% of the company's stock.
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
